Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutated Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03382795
What this trial is testing

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Korea University Guro Hospital 63
Testing effectiveness (Phase 2)Ended earlyNCT03784599
What this trial is testing

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 28
Testing effectiveness (Phase 2)UnknownNCT03062800
What this trial is testing

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Who this might be right for
Advanced Nsclc
Qilu Hospital of Shandong University 232
Large-scale testing (Phase 3)Not Yet RecruitingNCT06323148
What this trial is testing

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Who this might be right for
Lung CancerEGFR Gene MutationMinimal Residual Disease
Fudan University 226
Post-approval studies (Phase 4)UnknownNCT02778893
What this trial is testing

Conmana Combined With Thalidomide to Treat NSCLC

Who this might be right for
NSCLC
Henan Provincial People's Hospital 67
Testing effectiveness (Phase 2)UnknownNCT01410214
What this trial is testing

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer Stage IIIA
Chinese Lung Cancer Surgical Group 80
Testing effectiveness (Phase 2)Study completedNCT02625168
What this trial is testing

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Who this might be right for
Lung Cancer
The University of Hong Kong 25
Testing effectiveness (Phase 2)Looking for participantsNCT07117890
What this trial is testing

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Non Small Cell Lung Cancer
Fudan University 34
Large-scale testing (Phase 3)Looking for participantsNCT05800223
What this trial is testing

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Shanghai Cancer Hospital, China 300
Testing effectiveness (Phase 2)UnknownNCT05435274
What this trial is testing

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 380
Large-scale testing (Phase 3)UnknownNCT01405079
What this trial is testing

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 222
Testing effectiveness (Phase 2)Looking for participantsNCT07379476
What this trial is testing

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)
Chinese University of Hong Kong 64
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Large-scale testing (Phase 3)Looking for participantsNCT07100080
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 500
Not applicableStudy completedNCT04105153
What this trial is testing

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Thoraxklinik-Heidelberg gGmbH 400
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970
What this trial is testing

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Who this might be right for
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
Daiichi Sankyo 586
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07807722
What this trial is testing

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)EGFRNeoadjuvant Therapy
Hubei Cancer Hospital 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Next Page